Currently out of the existing stock ratings of Ritu Baral, 115 are a BUY (89.15%), 13 are a HOLD (10.08%), 1 are a SELL (0.78%).

Ritu Baral

Work Performance Price Targets & Ratings Chart

Analyst Ritu Baral, currently employed at TD COWEN, carries an average stock price target met ratio of 57.36% that have a potential upside of 43.46% achieved within 500 days.

Ritu Baral’s has documented 262 price targets and ratings displayed on 30 stocks. The coverage is on Healthcare, Industrials sectors.

Most recent stock forecast was given on RNA, Avidity Biosciences at 29-Oct-2025.

Wall Street Analyst Ritu Baral

Analyst best performing recommendations are on SAGE (SAGE THERAPEUTIC).
The best stock recommendation documented was for SAGE (SAGE THERAPEUTIC) at 7/30/2024. The price target of $10 was fulfilled within 2 days with a profit of $0.8 (7.41%) receiving and performance score of 37.04.

Average potential price target upside

of $74.33 (40.08%) on MDGL (MADRIGAL PHARMACEUTICALS).
of $46.91 (42.54%) on ALNY (ALNYLAM PHARMACEUTICALS).
of $44.15 (152.88%) on GBT (GLOBAL BLOOD THERAPEUTICS).

ACAD ACADIA Pharmaceuticals ALBO Albireo Pharma ALNY Alnylam Pharmaceuticals AMRN Amarin PLC FOLD Amicus Therapeutics ICPT Intercept Pharmaceuticals KRYS Krystal Biotech MNTA Momenta Pharmaceuticals NGM NGM Biopharmaceuticals PTCT PTC Therapeutics SAGE Sage Therapeutic SPRB Spruce Biosciences SRPT Sarepta Therapeutics GBT Global Blood Therapeutics MYOK MyoKardia SPRO Spero Therapeutics APTX Aptinyx TERN Terns Pharmaceuticals INSM Insmed MDGL Madrigal Pharmaceuticals CYTK Cytokinetics MIST Milestone Pharmaceuticals QURE Uniqure NV BLU BELLUS Health RNA Avidity Biosciences ANTX AN2 Therapeutics ALDX Aldeyra The AXON Axon Enterprise ITCI Intracellular Th ORPH Orphazyme A/S

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Ami Fadia (NEEDHAM)